{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:43:19Z","timestamp":1783568599167,"version":"3.55.0"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014091","name":"AstraZeneca Pharma Poland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023368","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The outcomes and best treatment strategies for germline <jats:italic>BRCA1\/2<\/jats:italic> mutation (<jats:italic>gBRCAm<\/jats:italic>) carriers with metastatic breast cancer (MBC) remain uncertain. We compared the overall survival and the first line progression free survival (PFS1) of patients with a <jats:italic>gBRCAm<\/jats:italic> identified at initiation of first\u2010line treatment with those of <jats:italic>BRCA<\/jats:italic> wild\u2010type (WT) and not\u2010tested (NT) individuals in the ESME real\u2010world database of MBC patients between 2008 and 2016 (NCT03275311). Among the 20\u2009624 eligible patients, 325 had a <jats:italic>gBRCAm<\/jats:italic>, 1138 were WT and 19\u2009161 NT. Compared with WT, <jats:italic>gBRCAm<\/jats:italic> carriers were younger, and had more aggressive diseases. At a median follow\u2010up of 50.5\u00a0months, median OS was 30.6 (95%CI: 21.9\u201034.3), 35.8 (95%CI: 32.2\u201037.8) and 39.3\u00a0months (95% CI: 38.3\u201040.3) in the <jats:italic>gBRCAm<\/jats:italic>, WT and NT subgroups, respectively. Median PFS1 was 7.9 (95%CI: 6.6\u20109.3), 7.8 (95%CI: 7.3\u20108.5) and 9.7\u00a0months (95%CI, 9.5\u201010.0). In the multivariable analysis conducted in the whole cohort, g<jats:italic>BRCA<\/jats:italic>m status had however no independent prognostic impact on OS and PFS1. Though, in the triple\u2010negative subgroup, g<jats:italic>BRCA<\/jats:italic>m patients had better OS and PFS1 (HR vs WT\u00a0=\u00a00.76; 95%CI: 0.60\u20100.97; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.027 and 0.69; 95% CI: 0.55\u20100.86; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.001, respectively). In contrast, in patients with HR+\/HER2 negative cancers, PFS1 appeared significantly and OS non significantly lower for g<jats:italic>BRCA<\/jats:italic>m carriers (PFS1: HR vs WT\u00a0=\u00a01.23; 95%CI: 1.03\u20101.46; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.024; OS:HR\u00a0=\u00a01.22, 95% CI: 0.97\u20101.52, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.089). In conclusion, g<jats:italic>BRCA1\/2<\/jats:italic> status appears to have divergent survival effects in MBC according to IHC subtype.<\/jats:p>","DOI":"10.1002\/ijc.34304","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T10:33:35Z","timestamp":1664188415000},"page":"921-931","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Survival outcomes of metastatic breast cancer patients by germline <i>BRCA1\/2<\/i> status in a large multicenter real\u2010world database"],"prefix":"10.1002","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0475-8631","authenticated-orcid":false,"given":"Audrey","family":"Mailliez","sequence":"first","affiliation":[{"name":"Center Oscar Lambret  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"D'Hondt","sequence":"additional","affiliation":[{"name":"Institut r\u00e9gional du Cancer Montpellier\/Val d'Aurelle  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Lusque","sequence":"additional","affiliation":[{"name":"Institut Claudius Regaud, IUCT\u2010Oncopole  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Caron","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5515-9180","authenticated-orcid":false,"given":"Luc","family":"Cabel","sequence":"additional","affiliation":[{"name":"Institut Curie  Paris et Saint Cloud France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Goncalves","sequence":"additional","affiliation":[{"name":"Institut Paoli\u2010Calmette  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Debled","sequence":"additional","affiliation":[{"name":"Institut Bergoni\u00e9  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gladieff","sequence":"additional","affiliation":[{"name":"Institut Claudius Regaud, IUCT\u2010Oncopole  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Marc","family":"Ferrero","sequence":"additional","affiliation":[{"name":"Center Antoine Lacassagne  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Petit","sequence":"additional","affiliation":[{"name":"Center Paul Strauss  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Ange","family":"Mouret\u2010Reynier","sequence":"additional","affiliation":[{"name":"Center Jean Perrin  Clermont Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Christophe","family":"Eymard","sequence":"additional","affiliation":[{"name":"Institut Jean Godinot  Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Levy","sequence":"additional","affiliation":[{"name":"Center Fran\u00e7ois Baclesse  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Uwer","sequence":"additional","affiliation":[{"name":"Institut de Cancerologie de Lorraine  Vandoeuvre\u2010l\u00e8s\u2010Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Leheurteur","sequence":"additional","affiliation":[{"name":"Center Henri Becquerel  Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Desmoulins","sequence":"additional","affiliation":[{"name":"Center Georges Fran\u00e7ois Leclerc  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[{"name":"Center L\u00e9on B\u00e9rard  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Sebastien","family":"Frenel","sequence":"additional","affiliation":[{"name":"Institut de canc\u00e9rologie de l'Ouest  Nantes et Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"de la Motte Rouge","sequence":"additional","affiliation":[{"name":"Center Eug\u00e8ne Marquis  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtane","family":"Simon","sequence":"additional","affiliation":[{"name":"Unicancer  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-061X","authenticated-orcid":false,"given":"William","family":"Jacot","sequence":"additional","affiliation":[{"name":"Institut r\u00e9gional du Cancer Montpellier\/Val d'Aurelle  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.010"},{"issue":"103","key":"e_1_2_12_3_1","first-page":"356","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"2018","author":"Ferlay J","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"96","key":"e_1_2_12_4_1","first-page":"17","article-title":"Time trends of overall survival among metastatic breast cancer patients in the real\u2010life ESME cohort","volume":"2018","author":"Gobbini E","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.5985"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01200"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S206949"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-11-0775"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.0463"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"e0120189","DOI":"10.1371\/journal.pone.0120189","article-title":"Worse breast cancer prognosis of BRCA1\/BRCA2 mutation carriers: what's the evidence? A systematic review with meta\u2010analysis","volume":"10","author":"Broek AJ","year":"2015","journal-title":"PLoS One"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30891-4"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1007"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1691"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz012"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"e_1_2_12_17_1","first-page":"CD011395","article-title":"PARP (poly ADP\u2010ribose polymerase) inhibitors for locally advanced or metastatic breast cancer","volume":"4","author":"Taylor AM","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023568"},{"issue":"129","key":"e_1_2_12_19_1","first-page":"60","article-title":"Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008\u20102016","volume":"2020","author":"Deluche E","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw329\/3064570"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.01.006"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095285"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0009-7"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060738"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0376-y"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-021-00162-4"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215"},{"issue":"146","key":"e_1_2_12_28_1","first-page":"30","article-title":"Clinical practice guidelines for BRCA1 and BRCA2 genetic testing","volume":"2021","author":"Pujol P","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S189627"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0017"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0127-5"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.28142"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-0996-9"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3697-z"},{"key":"e_1_2_12_35_1","unstructured":"Association Des \u00c9pid\u00e9miologistes de Langue Fran\u00e7aise ADELF.Deontologie et bonnes pratiques en epidemiologie recommandations revisees [Internet].2007.http:\/\/adelf.isped.u-bordeaux2.fr\/Portals\/0\/DOCUMENTATION\/Recommandations%202%20-%20Version%20finale-France-Aout%202007.pdf"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1082"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.34304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.34304","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.34304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T01:37:46Z","timestamp":1692495466000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.34304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/ijc.34304"],"URL":"https:\/\/doi.org\/10.1002\/ijc.34304","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]},"assertion":[{"value":"2022-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}